NW Bio: Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024

Northwest Biotherapeutics, Inc. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported revenue was USD 1.38 million compared to USD 1.93 million a year ago. Net loss was USD 83.78 million compared to USD 62.6 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.06 a year ago. Northwest Biotherapeutics, Inc. reported earnings results for the full year ended December 31, 2024. For the full year, the company reported revenue was USD 1.38 million compared to USD 1.93 million a year ago. Net loss was USD 83.78 million compared to USD 62.6 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.06 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.06 a year ago.